Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MLYS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMineralys buys out lorundrostat royalties for $200M, secures up to $500M debt facility
Filed June 3, 2026 · Period ending June 2, 2026 · ~1 min read
Key Changes
-
high
MLYS paid Tanabe $200M upfront to eliminate all future royalty obligations on lorundrostat sales, converting to a royalty-free perpetual license while retaining up to $365M in commercial milestone payments.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
Secured up to $500M term loan facility maturing June 2031: $100M drawn immediately, $150M Tranche B requires FDA approval by April 2027, and $250M in optional tranches tied to approval plus sales milestones.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
If lorundrostat NDA is not approved by September 30, 2027, MLYS must repay all outstanding term loans in four equal quarterly installments starting that date.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
Term loans bear interest at SOFR (3.25% floor) plus 5.50% with 2% funding fees, secured by substantially all company assets including intellectual property.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
Financial covenants include minimum liquidity requirements until FDA approval and minimum trailing-twelve-month product revenue starting in 2028/2029.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
Summary
Mineralys executed a major capital restructuring centered on its lead asset lorundrostat, a treatment for uncontrolled hypertension. The company paid Tanabe $200 million upfront to eliminate all future royalty obligations, converting its license to royalty-free status.
This improves lorundrostat's unit economics if commercialized, though the company retains up to $365 million in commercial milestone obligations tied to first sale and revenue targets.
To fund the buyout and commercialization, MLYS secured a $500 million senior secured term loan facility from Pharmakon-managed funds, drawing $100 million immediately with additional tranches contingent on FDA approval and sales performance. The financing structure creates meaningful regulatory risk. If the lorundrostat NDA is not approved by September 30, 2027, the company must repay all outstanding debt in four equal quarterly installments starting that date. This hard deadline ties the company's financial flexibility directly to FDA action. The loan carries interest around 8.75% (SOFR floor plus spread) and is secured by substantially all assets including intellectual property. For investors, the transaction trades ongoing royalty obligations for upfront debt, betting that lorundrostat approval and commercial success will justify the leverage and enable access to the additional $350 million in optional tranches.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
MLYS amended its lorundrostat license to eliminate royalties for $200M upfront plus milestones, and secured a $500M term loan facility.
Added in current filing · verify on EDGAR →
Upon execution of the Amendment, the Company will make a one-time cash payment to Tanabe of $200.0 million and additional commercial milestone payments of up to $100.0 million in the aggregate (the “New Milestones”). As a result of entering into the Amendment, the Company will have remaining obligations to pay Tanabe commercial milestone payments of up to $255.0 million in the aggregate upon first commercial sale and upon meeting certain annual sales targets, as well as additional commercial milestone payments of up to $10.0 million for a second indication ... The Company will no longer be obligated to make any royalty payments to Tanabe for sales of lorundrostat by the Company, its affiliates or its sublicensees.
Mineralys restructured its lorundrostat license with Tanabe, paying $200 million upfront to eliminate all future royalty obligations and convert to a royalty-free, perpetual license. The company retains commercial milestone obligations totaling up to $365 million ($255M for primary indication, $100M new milestones, $10M second indication), but removes the ongoing royalty burden that would have applied to all product sales. This buyout provides greater economic certainty and improved unit economics for lorundrostat commercialization.
Added in current filing · verify on EDGAR →
On June 2, 2026 (the “Closing Date”), the Company entered into a senior secured term loan agreement (the “Loan Agreement”) with BioPharma Credit PLC, as collateral agent (the “Agent”), and each of BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, which are funds managed by Pharmakon Advisors, LP, as lenders. The Loan Agreement provides for a five-year senior secured term loan, which matures on June 3, 2031 (the “Maturity Date”), for up to $500.0 million in term loans and consists of the following tranches (collectively, the “Term Loans”): (1) a Tranche A Loan of $100.0 million drawn on the Closing Date, (2) a Tranche B Loan of $150.0 million, which will be required to be drawn by no later than April 30, 2027, subject to the approval by the U.S. Food and Drug Administration (the “FDA”) of the lorundrostat New Drug Application (“NDA”) (the “Tranche B Approval Condition”), (3) a Tranche C Loan of $150.0 million, which will be available at the Company’s election until December 14, 2028, subject to the occurrence of the Tranche B Approval Condition and the achievement of certain milestones in respect of certain net sales levels, and (4) a Tranche D Loan of $100.0 million, which will be available at the Company’s election until June 14, 2029, subject to the Company’s draw of the Tranche C Loan and the achievement of certain milestones in respect of certain net sales levels.
Mineralys secured a $500 million senior secured term loan facility maturing June 2031, structured in four tranches. Tranche A ($100M) was drawn immediately; Tranche B ($150M) requires FDA approval of the lorundrostat NDA by April 2027; Tranches C and D ($150M and $100M) are optional and contingent on FDA approval plus achieving specified net sales milestones. This debt financing provides capital to fund the $200 million Tanabe payment, lorundrostat commercialization, and operations, with future tranches tied to regulatory and commercial success.
Added in current filing · verify on EDGAR →
The Term Loans bear interest at a rate based upon an annual interest rate of 3-month secured overnight financing rate (subject to a 3.25% floor) plus 5.50%, payable quarterly in arrears. The Company is required to pay a funding fee equal to 2.00% of the funding amount on the funding date for each Term Loan.
The term loans carry interest at SOFR (3.25% floor) plus 5.50%, payable quarterly, with a 2% funding fee on each tranche draw. At current rates, this implies an effective interest rate around 8.75% plus the 2% upfront fee, representing typical life sciences debt pricing for a pre-commercial biotech.
Added in current filing · verify on EDGAR → · paraphrased
The Company's obligations under the Loan Agreement are secured by substantially all of its assets, including its intellectual property... The Loan Agreement contains the following financial covenants: (i) at all times prior to the satisfaction of the Tranche B Approval Condition, a minimum liquidity requirement and (ii) with respect to the fiscal year ending December 31, 2028 and then tested quarterly commencing with the fiscal quarter ending March 31, 2029 and at the end of each fiscal quarter thereafter, a minimum trailing twelve months consolidated net product revenue covenant.
The loan is secured by substantially all company assets including intellectual property. Financial covenants include minimum liquidity requirements until FDA approval and minimum trailing-twelve-month product revenue starting in 2028/2029. The company also faces restrictions on asset sales, additional debt, dividends, and change-of-control transactions unless the loan is repaid in full.
Added in current filing · verify on EDGAR →
The Term Loans are subject to certain mandatory prepayments, including a repayment in full of all term loans in four equal payments commencing on September 30, 2027 to the extent the Tranche B Approval Condition is not met on or prior to September 30, 2027.
If lorundrostat does not receive FDA approval by September 30, 2027, Mineralys must repay all outstanding term loans in four equal quarterly installments starting that date. This creates significant regulatory risk: failure to achieve approval on schedule would trigger immediate debt repayment obligations that could strain liquidity and force asset sales or equity raises.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify